Tilray Medical wins INFARMED approval for in-house quality testing at Portugal EU-GMP facility

By Public Technologies
  • Tilray Medical secured INFARMED clearance for on-site microbiological and chemical/physical quality testing at its EU-GMP Cantanhede facility.
  • Move brings critical batch-release testing in-house, speeding product release across regulated medical cannabis markets.
  • Shift reduces reliance on third-party labs, lowering release costs and shortening timelines from harvest to sale.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tilray Brands Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610130700OMX_____CNEWS_EN_GNW9844214_en) on October 13, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk